Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Investigational New Drugs
JournalCitation impact & published research
Investigational New Drugs is a journal indexed in ScholarIQ from OpenAlex. ScholarIQ records 4,011 works, 108,399 citations, an h-index of 115 and an APC (USD) of 4,390.
4,011
Works
108,399
Citations
115
h-index
4,390
APC (USD)
IDs:OpenAlex
What are the most-cited papers on Investigational New Drugs?
ScholarIQmost cited works
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study
Stefan von Delius, Florian Eckel, Stefan Wagenpfeil, Martina Mayr, Konrad Stock, Frank Kullmann, Florian Obermeier, Johannes Erdmann, Renate Schmelz, Stefan Quasthoff, Helmuth Adelsberger, Rainer Bredenkamp, Roland M. Schmid, C. Lersch
Investigational New Drugs. 200690 Citations
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Yasuhito Fujisaka, Takayasu Kurata, Kaoru Tanaka, Toshihiro Kudo, Kunio Okamoto, Junji Tsurutani, Hiroyasu Kaneda, Isamu Okamoto, Masayuki Namiki, Chifumi Kitamura, Kazuhiko Nakagawa
Investigational New Drugs. 201453 CitationsOPEN ACCESS
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Michael Thomas, Parvis Sadjadian, Jens Kollmeier, Jamie Lowe, Paulette Mattson, J. Richard Trout, Michele Gargano, Myra L. Patchen, Richard M. Walsh, Martin Béliveau, Jean‐Francois Marier, Nandita Bose, Keith Gorden, Folker Schneller
Investigational New Drugs. 201753 CitationsOPEN ACCESS
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
Marie Bréchon, Marie Dior, Johann Dréanic, Bertrand Brieau, Marie‐Anne Guillaumot, Catherine Brézault, Olivier Mir, François Goldwasser, Romain Coriat
Investigational New Drugs. 201737 Citations
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
Nikita Volkov, Grigoriy A. Yanus, Alexandr O. Ivantsov, Fedor Moiseenko, Olga G. Matorina, Ilya V. Bizin, Vladimir Moiseyenko, Evgeny N. Imyanitov
Investigational New Drugs. 201932 Citations
Related on ScholarIQ
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study
Paper
Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Paper
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Paper
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers
Paper
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
Paper
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy
Paper